Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis

Van den broecke, Astrid; Van Coile, Laura; Decruyenaere, Alexander; Colpaert, Kirsten; Benoit, Dominique; Van Vlierberghe, Hans; Decruyenaere, Johan

doi:10.1186/s13613-018-0356-z

Annals of Intensive Care

Table 1 Characteristics of patients with HH classified by in-hospital 28-day mortality

From: Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis

Variable	Patients				Variable	Patients
	Total (n = 1116)	In-hospital 28-day mortality		P		Total (n = 1116)	In-hospital 28-day mortality		P
	Total (n = 1116)	No (n = 614)	Yes (n = 502)	P		Total (n = 1116)	No (n = 614)	Yes (n = 502)	P
Sex^a					ASTmax^a
Male	61.3% (684)	62.2% (382)	60.2% (302)	0.483	5–10× ULN	35.4% (395)	43.0% (264)	26.1% (131)	< 0.001
Age^b (year)	66.0 (55.0–74.0)	63.0 (53.0–73.0)	68.0 (58.0–76.8)	< 0.001	10–20× ULN	23.4% (261)	23.6% (145)	23.1% (116)	0.985
BMI^b (kg/m²)	25.4 (22.9–28.9)	25.4 (23.0–28.5)	25.4 (22.9–29.4)	0.774	> 20× ULN	41.2% (460)	33.4% (205)	50.8% (255)	< 0.001
Cause^a					Supportive therapy^c
Cardiac failure	49.1% (548)	52.3% (321)	45.2% (227)	0.103	Ventilation^a	74.9% (836)	66.4% (408)	85.3% (428)	< 0.001
Septic shock	29.8% (333)	25.6% (157)	35.1% (176)	0.003	Medication
Hypovolemic shock	9.4% (105)	9.6% (59)	9.2% (46)	0.999	Inotropic agents^a	43.2% (482)	39.3% (241)	48.0% (241)	0.003
Acute respiratory failure	6.4% (71)	7.0% (43)	5.6% (28)	0.927	Vasopressor agents^a	60.8% (678)	51.1% (314)	72.5% (364)	< 0.001
Acute on chronic respiratory failure	3.3% (37)	3.7% (23)	2.8% (14)	0.956	Dialysis^a	9.5% (106)	6.8% (42)	12.7% (64)	< 0.001
Pulmonary embolism	1.4% (16)	1.1% (7)	1.8% (9)	0.945	IABP^a	17.5% (195)	19.5% (120)	14.9% (75)	0.044
Hyperthermia	0.5% (6)	0.7% (4)	0.4% (2)	0.995	LOS
Comorbidities					ICU^b (day)	4.4 (1.2–11.7)	6.4 (2.7–17.7)	1.8 (0.4–7.1)	< 0.001
Echocardio^a					Hospital^b (day)	12.1 (3.0–28.9)	25.7 (13.9–48.1)	2.1 (0.4–8.1)	< 0.001
Overall				0.406	Duration
Normal	40.0% (446)	42.0% (258)	37.5% (188)	–	Episode of HH^b (h)	54.3 (26.4–94.2)	53.4 (23.9–94.2)	56.7 (30.7–94.1)	0.527
LV dysfunction	25.1% (280)	23.5% (144)	27.1% (136)	–	Recovery of HH^b (h)	34.7 (14.6–67.2)	35.5 (14.1–68.0)	32.6 (16.2–61.4)	0.393
Missing	22.2% (248)	22.5% (151)	23.3% (117)	–	28-day mortality
LV and RV dysfunction	8.0% (89)	8.0% (49)	8.0% (40)	–	ICU^a	40.8% (455)	0.0% (0)	90.6% (455)	< 0.001
RV dysfunction	4.7% (53)	5.2% (32)	4.2% (21)	–	In-hospital^a	45.0% (502)	0.0% (0)	100.0% (502)	< 0.001
DM^a	18.7% (209)	17.4% (107)	20.3% (102)	0.218
Chronic respiratory failure^a	11.4% (127)	10.7% (66)	12.2% (61)	0.287
SOI scores^c
APS-II^b	28.0 (21.0–34.0)	25.0 (18.0–32.0)	30.0 (24.0–35.2)	0.005
SAPS-II^b	66.0 (46.0–81.0)	54.0 (36.0–71.0)	76.0 (58.0–89.0)	< 0.001

APS-II acute physiology II, AST aspartate aminotransferase, ASTmax maximum AST value, BMI body mass index, HH hypoxic hepatitis, IABP intra-aortic balloon pump, ICU intensive care unit, LOS length of stay, LV left ventricle, P P value, Q1 first quartile, Q3 third quartile, RV right ventricle, SAPS-II simplified acute physiology II, SOI severity of illness, T-ASTmax time point of maximum AST value, ULN upper limit of normal
Italics indicate the significant P values
^a% (n)
^bMedian (Q1–Q3)
^cAt T-ASTmax ± 12 h

Back to article page